Abstract 174P
Background
Application of computer and artificial intelligence (AI) has made revolutionary progress in medical fields. Computer-assisted diagnosis (CAD) on pathology is successful in diagnosis, classification, staging and predicting prognosis of cancer.
Methods
In this work, we used the technique of convolutional neural networks (CNN) for training of morphological images of gastric cancer, which is a promising application of artificial intelligence technique for medical image analysis, especially for cancer pathology.
Results
We introduced successful works of AI-aided gastric cancer analysis for over 300 cases. AI-assisted pathology technique could help the pathologist in detecting and locating the abnormal area in images and to diagnose and classify benign or malignant tissues. Therefore, AI exactly improves the diagnostic status of gastric cancer, such as in interpretation of medical images and classification between benign and cancerous tissues. The complete workflow of AI diagnosis for gastric cancer is under construction. AI is more useful in releasing pathologists from repeated work, and improving efficiency.
Conclusions
In conclusions, there are still notable technical obstacles before this approach can be used to improve conventional clinical practice. Higher performance needs corrected marking images by experienced pathologist and require ‘training’ algorithms on tremendous data. We stressed the importance of proper algorithms for improving confidence of analytic results that is close to human experts. Additionally, we indicated the gaps in current research and principal resolutions for advancing the field.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors without further recourse to the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract